|
1
|
Stulc T and Sedo A: Inhibition of
multifunctional dipeptidyl peptidase-IV: is there a risk of
oncological and immunological adverse effects? Diabetes Res Clin
Pract. 88:125–131. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Choudhury SR, Datta A, Chanda S, et al:
Overview of current and upcoming strategies implied for the therapy
of type 2 diabetes mellitus. Curr Diabetes Rev. 10:275–282. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Eurich DT, McAlister FA, Blackburn DF, et
al: Benefits and harms of antidiabetic agents in patients with
diabetes and heart failure: systematic review. BMJ. 335:4972007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Saenz A, Fernandez-Esteban I, Mataix A, et
al: Metformin monotherapy for type 2 diabetes mellitus. Cochrane
Database Syst Rev. 3:CD0029662005.PubMed/NCBI
|
|
5
|
IDF Clinical Guidelines Task Force. Global
Guideline for Type 2 Diabetes: recommendations for standard,
comprehensive, and minimal care. Diabet Med. 23:579–593. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
National Collaborating Centre for Chronic
Conditions (UK). Type 2 Diabetes: National Clinical Guideline for
Management in Primary and Secondary Care (Update). National
Institute for Health and Clinical Excellence: Guidance. Royal
College of Physicians; London: 2008
|
|
7
|
American Diabetes Association. Standards
of medical care in diabetes - 2009. Diabetes Care. 32(Suppl 1):
S13–S61. 2009. View Article : Google Scholar
|
|
8
|
American Diabetes Association. Standards
of medical care in diabetes - 2010. Diabetes Care. 33(Suppl 1):
S11–S61. 2010. View Article : Google Scholar
|
|
9
|
Nathan DM, Buse JB, Davidson MB, et al;
American Diabetes Association and the European Association for
Study of Diabetes. Medical management of hyperglycemia in type 2
diabetes: a consensus algorithm for the initiation and adjustment
of therapy: a consensus statement of the American Diabetes
Association and the European Association for the Study of Diabetes.
Diabetes Care. 32:193–203. 2009. View Article : Google Scholar :
|
|
10
|
Inzucchi SE: Oral antihyperglycemic
therapy for type 2 diabetes: scientific review. JAMA. 287:360–372.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goldstein BJ, Feinglos MN, Lunceford JK,
et al; Sitagliptin 036 Study Group. Effect of initial combination
therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and
metformin on glycemic control in patients with type 2 diabetes.
Diabetes Care. 30:1979–1987. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Charbonnel B, Karasik A, Liu J, et al;
Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl
peptidase-4 inhibitor sitagliptin added to ongoing metformin
therapy in patients with type 2 diabetes inadequately controlled
with metformin alone. Diabetes Care. 29:2638–2643. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Williams-Herman D, Johnson J, Teng R, et
al: Efficacy and safety of initial combination therapy with
sitagliptin and metformin in patients with type 2 diabetes: a
54-week study. Curr Med Res Opin. 25:569–583. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Arechavaleta R, Seck T, Chen Y, et al:
Efficacy and safety of treatment with sitagliptin or glimepiride in
patients with type 2 diabetes inadequately controlled on metformin
monotherapy: a randomized, double-blind, non-inferiority trial.
Diabetes Obes Metab. 13:160–168. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Koren S, Shemesh-Bar L, Tirosh A, et al:
The effect of sitagliptin versus glibenclamide on arterial
stiffness, blood pressure, lipids, and inflammation in type 2
diabetes mellitus patients. Diabetes Technol Ther. 14:561–567.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nauck MA, Meininger G, Sheng D, et al;
Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl
peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea,
glipizide, in patients with type 2 diabetes inadequately controlled
on metformin alone: a randomized, double-blind, non-inferiority
trial. Diabetes Obes Metab. 9:194–205. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Seck T, Nauck M, Sheng D, et al;
Sitagliptin Study 024 Group. Safety and efficacy of treatment with
sitagliptin or glipizide in patients with type 2 diabetes
inadequately controlled on metformin: a 2-year study. Int J Clin
Pract. 64:562–576. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Srivastava S, Saxena GN, Keshwani P and
Gupta R: Comparing the efficacy and safety profile of sitagliptin
versus glimepiride in patients of type 2 diabetes mellitus
inadequately controlled with metformin alone. J Assoc Physicians
India. 60:27–30. 2012.PubMed/NCBI
|
|
19
|
Li WH, Lin M and Zhang XJ: Comparison on
adding sitagliptin or glimepiride in poorly controlled overweight
type 2 diabetes with oral metformin. Zhongguo Yi Yuan Yao Xue Za
Zhi. 32:792–794. 2012.(In Chinese).
|
|
20
|
Higgins JPT and Altman DG: Assessing risk
of bias in included studies. Cochrane Handbook for Systematic
Reviews of Interventions. Higgins JPT and Green S: John Wilry &
Sons; Chichester: pp. 187–241. 2008, View Article : Google Scholar
|
|
21
|
DeFronzo RA: Pharmacologic therapy for
type 2 diabetes mellitus. Ann Intern Med. 131:281–303. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Inzucchi SE: Oral antihyperglycemic
therapy for type 2 diabetes: scientific review. JAMA. 287:360–372.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bergman AJ, Stevens C, Zhou Y, et al:
Pharmacokinetic and pharmacodynamic properties of multiple oral
doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a
double-blind, randomized, placebo-controlled study in healthy male
volunteers. Clin Ther. 28:55–72. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Herman GA, Stevens C, Van Dyck K, et al:
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor
of dipeptidyl peptidase IV, in healthy subjects: results from two
randomized, double-blind, placebo-controlled studies with single
oral doses. Clin Pharmacol Ther. 78:675–688. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Maedler K, Carr RD, Bosco D, et al:
Sulfonylurea induced beta-cell apoptosis in cultured human islets.
J Clin Endocrinol Metab. 90:501–506. 2005. View Article : Google Scholar
|
|
26
|
Drucker DJ: Enhancing incretin action for
the treatment of type 2 diabetes. Diabetes Care. 26:2929–2940.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Krentz AJ and Bailey CJ: Oral antidiabetic
agents: current role in type 2 diabetes mellitus. Drugs.
65:385–411. 2005. View Article : Google Scholar : PubMed/NCBI
|
